According to TipRanks.com, Arce is a 5-star analyst with an average return of 17.1% and a 43.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Paratek Pharmaceuticals with a $18.00 average price target.
See today’s analyst top recommended stocks >>
Based on Paratek Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $8.97 million and GAAP net loss of $27.37 million. In comparison, last year the company earned revenue of $17.02 million and had a GAAP net loss of $22.79 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.